The Brand Name CRIXAN Has Generic Salt :: Clarithromycin
CRIXAN Is From Company Rexcel Priced :: Rs. 139.51
CRIXAN have Clarithromycin is comes under Sub class Macrolides of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Macrolides
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Respiratory tract infections, Skin and soft tissue infections, Leprosy, peptic ulcer disease, pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia, legionellosis, Helicobacter pylori, lyme disease, Community-Acquired Pneumonia
Drug Dose ::
Adult: PO Resp tract infections; Skin and soft tissue infections; Susceptible infections 250 mg twice daily, up to 500 mg twice daily for severe infections, for 7-14 days. Mycobacterium avium complex infections W/ other antimycobacterials: 500 mg twice daily. Leprosy As part of multidrug therapy: 500 mg/day. H. pylori infection W/ another antibacterial and either a proton pump inhibitor or H2 antagonist: 500 mg twice daily for 7-14 days. IV Resp tract infections; Skin and soft tissue infections; Susceptible infections 500 mg twice daily for 2-5 days. Child: 7.5 mg/kg bid for 5-10 days. Renal impairment: CrCl (ml/min) <30 half the dosage or double dosing interval. Contraindication ::
Hypersensitivity. Patients receiving terfenadine, astemizole, pimozide, cisapride and ergot derivatives. Pregnancy; history of acute porphyria.
Drug Precautions ::
Renal and hepatic impairment; macrolide cross-resistance; lactation, children.
Drug Side Effects ::
GI upset, glossitis, stomatitis, altered taste; headache, dizziness, hallucinations, insomnia, other CNS effects; rash; hepatic dysfunction, Potentially Fatal: Pseudomembranous colitis, anaphylaxis, Stevens-Johnson syndrome.
Pregnancy category ::
Drug Mode of Action ::
Clarithromycin inhibits protein synthesis by binding to 50s ribosomal subunits of susceptible organisms. It has activity against susceptible streptococci and staphylococci as well as other species including B. catarrhalis, L. spp, C. trachomatis and U. urealyticum.
Drug Interactions ::
Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam). Potentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.